Tumor Lysis Syndrome after Propranolol Therapy in Ulcerative Infantile Hemangioma: Rare Complication or Incidental Finding?

Dermatology ◽  
2012 ◽  
Vol 224 (2) ◽  
pp. 106-109 ◽  
Author(s):  
R. Cavalli ◽  
R.B. Buffon ◽  
M. de Souza ◽  
A.M. Colli ◽  
C. Gelmetti
Keyword(s):  
Incidental Finding ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
Infantile Hemangioma ◽  
Tumor Lysis ◽  
Propranolol Therapy

Pretreatment Tumor Lysis Syndrome Associated with Bulky Retroperitoneal Tumors. Recognition is the Mainstay of Therapy

2006 ◽  
Vol 92 (6) ◽  
pp. 540-541
Author(s):  
Dimitrios Theodorou ◽  
Emmanuel Lagoudianakis ◽  
Michael Pattas ◽  
Panagiotis Drimousis ◽  
Dimitrios K Tsekouras ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Differential Diagnosis ◽  
Early Recognition ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
Clinical Entity ◽  
Tumor Lysis ◽  
Aggressive Management ◽  
Retroperitoneal Tumors

Acute pretreatment tumor lysis syndrome is a rare complication of cancer. Early recognition and aggressive management are mandatory for prevention of the adverse sequelae of the syndrome. Here we present 2 cases of pretreatment tumor lysis syndrome, concluding that this clinical entity should be in the differential diagnosis of acute renal failure associated with malignancy, as early recognition is in fact the mainstay of treatment.

Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report

2016 ◽  
Vol 23 (3) ◽  
pp. 235-239 ◽  
Author(s):  
Varinder Kaur ◽  
Arjun Swami
Keyword(s):  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Tumor Lysis ◽  
Mantle Cell ◽  
Hodgkin's Lymphomas

Mantle cell lymphoma accounts for 5–7% of all non-Hodgkin’s lymphomas. Under the current WHO classification, it is categorized as an indolent B cell lymphoma, but has an aggressive clinical course. New insights into leukemogenic molecular pathways of mantle cell lymphoma have uncovered unique therapeutic targets. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma. Long-term studies have shown that grade 3 or 4 adverse events are infrequent. Asymptomatic lymphocytosis is frequently seen with ibrutinib use in mantle cell lymphoma; however, tumor lysis syndrome is an extremely rare complication. To date, only two patients with ibrutinib-associated tumor lysis syndrome in mantle cell lymphoma have been described in a long-term follow-up study. Both patients met laboratory criteria for tumor lysis syndrome, however, but did not develop clinical tumor lysis syndrome. We, here describe a patient with relapsed mantle cell lymphoma who developed clinical tumor lysis syndrome with ibrutinib monotherapy.

scholarly journals Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer

2021 ◽  
Vol 28 (1) ◽  
pp. 440-444
Author(s):  
Sidra Javed
Keyword(s):  
Prostate Cancer ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
Adverse Outcomes ◽  
Normocytic Anemia ◽  
Tumor Lysis ◽  
Oncological Emergency ◽  
Urate Nephropathy ◽  
Uremic Syndrome ◽  
Baseline Renal Function

Prostate cancer can masquerade as just normocytic anemia and thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or tumor lysis syndrome (TLS). We are reporting an intriguing case of metastatic prostate cancer which remained undiagnosed until the patient showed signs of tumor lysis syndrome (TLS), leading to urate nephropathy requiring urgent hemodialysis. Tumor lysis syndrome is an oncological emergency but an exceedingly rare complication in non-hematological malignancies, including prostate cancer. It is challenging to recognize features of TLS in a case such as this with an unknown diagnosis. In the case of an established diagnosis of malignancy, however, checking baseline renal function, uric acid, lactate dehydrogenase (LDH), potassium, and phosphate to monitor for TLS as well as considering urate lowering therapy can help prevent adverse outcomes.

scholarly journals Chronic lymphocytic leukemia; an incidental finding in a COVID-19 patient.

2021 ◽  
Author(s):  
Shazaf Masood Sidhu ◽  
Fabiha Ghulam Muhammad ◽  
Ainan Arshad
Keyword(s):  
Acute Kidney Injury ◽  
Chronic Lymphocytic Leukemia ◽  
Incidental Finding ◽  
Tumor Lysis Syndrome ◽  
Kidney Injury ◽  
Functional Class ◽  
Lymphocytic Leukemia ◽  
Shortness Of Breath ◽  
Tumor Lysis ◽  
History Of

Abstract We report a case of 57 years old male, with no prior comorbids functional class I, presented with a history of fever for one week along with shortness of breath and cough for 5 days. Upon workup his baseline CBC reported bicytopenia along with marked lymphocytosis which raised the suspicion and to confirm the diagnosis, his acute leukemia comprehensive panel was done which reported an incidental finding of Chronic lymphocytic leukemia along with concomitant COVID PCR positive. This patient also presented with Tumor Lysis Syndrome and Acute kidney Injury.

scholarly journals Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication!

2015 ◽  
Vol 6 (5) ◽  
pp. 464-471 ◽  
Author(s):  
Chanudi Weerasinghe ◽  
Mazen Zaarour ◽  
Sami Aranout ◽  
Gwenalyn Garcia ◽  
Meekoo Dhar
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rare Complication ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Spontaneous Tumor Lysis Syndrome
Sign in / Sign up

Export Citation Format

Share Document